Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Wednesday, July 1

ORAL SESSIONS 15.00-17.00 15.00-17.0001

C37 Mother-to-Child HIV Transmission: o
New findings
Chairs: Ruth Wanjitzu Nduati, Ruth Webb
Venue: Session Hall V
Time: 15.00-17.00
456 Late postnatal mother-to-child transmission (LPT) of HIV-1: 23266
International multicentre pooled analysis
Valeriane Leroy*; M.L. Newell; F Dabis; C Peckham, France
457 HIV-infection due to breastfeeding in a cohort of babies 23270
not infected at enrollment
Taha Taha*; P Miotti; N. Kumwenda; H. Van Der Hoeven;
D. Markakis; D. Hoover; R. Biggar, USA
458 Control of maternal HIV-1 disease during pregnancy 12151
Karen Beckerman*; M. Benson; S. Dahud; M. Shannon, USA
459 Missed opportunities to reduce perinatal HIV transmission: 23273
Maternal and neonatal zidovudine (ZDV) use in
Los Angeles county (LAC)
Laurene Mascola*; Toni Frederick; J.Jackson; Y.S. Shin;
A. Kovacs; J. Bertolli, USA
460 Health care providers'awareness of the ACTG 076 42210
findings and their adherence to government guidelines
to reduce perinatal transmission of HIV
Kaenan Hertz*; D. Parham; L. Soto-Torres; S. Trent-Adams, USA
461 Association between placental malaria infection and 23268
increased risk of mother-to-infant transmission of HIV-1
in western Kenya
Bernard Nahlen*; Richard Steketee;J.Ayisi; A. Van Eijk;J. Otieno;
A. Misore; M. Rayfield; K. Udhayakumar, USA
462 Risk factors for perinatal HIV transmission in women/infants 23265
receiving standard zidovudine (ZDV) prophylaxis
John Lambert*; L. Mofenson; E.R. Stiehm;J. Bethel; W Meyer;
R Reichelderfer; G. Nemo, USA
463 Combination therapy with nevirapine, zidovudine and 12152
a second nucleoside analog during pregnancy
Francoise Kramer*; A. Stek;J. Homans; M. Khoury; A. Kovacs, USA
C38 Male and Female Condoms
Chairs: Monir Islam, Brenda Spencer
Venue: Session Hall VI
Time: 15.00-17.00
464 The condom user: ensuring the safety and acceptability of

D35 Bridging Session: Ethics and Science O
Chairs: Nobert Gilmore, June E. Osborn
Venue: Session Hall I
Time: 15.00-17.00
471 Additional unethical aspects of vertical transmission 44123
studies in developing countries
Peter G. Lurie* S.M. Wolfe, USA
472 Reply
Hoosen Coovadia
473 Developing policies on HIV/AIDS and pregnancy that respect 44101
law, ethics and human rights
Lori Stoltz*; L. Shop; R. Jurgens, Canada
474 Ethics in HIV/AIDS research in Kenya.The cases of Immunex, 44140
Kemron, Pearl Omega and Polyatomic Capheresis
(WDDS treatment)
Ambrose Rachier, Kenya
475 Ethical vs moral duties when HIV/AIDS clinical trials end 44126
Jose Luis Valdespino Gomez*; M.L. Garcia Garcia;
M. Palacios Martinez; L. Ferreyra Reyes; M.E. Mayor Maya;
M.E. Jimenez Corona; M. Ramos Madrigal, Mexico
476 Providing care, support and treatment to HIV-positive 44135
injection drug users: Legal and ethical issues
Eugene Oscapella*; R.E.F Jlrgens; D. Rilley; D. Roy;
T De Bruyn; E. Burnham, Canada
D36 Resource Allocation: How to Get the Most
Out of Limited Resources?
Chairs: Wences Msuya, Wiputh Poolcharoen
Venue: Session Hall II
Time: 15.00-17.00
477 Costing HIV using an observation database 24127
Dale Mc Murchy*; M. Millson; K. Leeb; RWH. Palmer;
G. Robinson; A. Rachlis; R. Wall, Canada
478 The impact of HIV/AIDS on the health sector in Uganda 43497
Harold Michael Jjemba*; E. Madraa; T Lutalo, Uganda
479 The cost-effectiveness of prophylaxis for mycobacterium 44238
avium complex in AIDS
Kenneth Freedberg*; J.A. Scharfstein; G.R. Seage, III; E. Losina;
M.C. Weinstein; D.E. Craven; A.D. Paltiel, USA
480 Costing HIV/AIDS:The Canadian HIV/AIDS economic 24122
research initiative
Janet Dubrack*; T. Albert; B. Jones; J. Martin; R. Shearer;
G. Williams, Canada
481 The affordability of antiretroviral therapy in developing 44245
countries: What policymakers need to know
Steven Forsythe, UK
482 Expansion of U.S. medicaid system to cover HIV drugs will 44241
prevent thousands of deaths and AIDS diagnoses, and is affordable
James G. Kahn*; B. Haile; S. W Chang, USA
483 Home-based nursing care:The cost effective way 22466
Lorna Scheepers, South Africa
484 Implicit valuation of a blood exclusion decision 44244
Edward H. Kaplan*, USA
Skills Building Workshops 15.00-18.30: see page 132
for details

the product
John Gerofi
465 The would-be condom user: making the right product
available at the right time
Patrick Friel
466 Free condoms/sold condoms:Which is actually used?
Lessons from the field in a remote district of Northern Uganda
Jacques Homsy*;J. W Idro; S. Tani; A. Odule; I. Juma; R. King;
D. Schopper, Uganda
467 Analysis of unit costs in 23 condom social marketing
programs 1990-1996
Guy Stallworthy, USA
468 Challenges to female condom intergration into condom
programming
Chuanchom Sakindhavat
469 The promise of female-controlled methods: Zimbabwe
experince of social marketing of female condom
Tsitsi Tsopotsa
470 New perspectives for condoms
James McIntyre

14263
44240

Pathway Symbols: O Gender O Human Rights O Policy O Youth and Children

CONFERENCE WORKBOOK

129